Product Information
PIMECROLIMUS 1% CREAM is a generic product labeled by Actavis Pharma, Inc., priced at $3.3861 per GM under NDC 00591294487. Its NADAC has been published 390 times since Apr 17, 2019.
FDA first approved this application on Dec 27, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/g
Manufacturer
Actavis Pharma, Inc.NDC
00591294487
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
PIMECROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA209345FDA Approved
12/27/2018
TE Code
AB
On Market Since
12/27/2018
Pharmacological Classes
Price Statistics
The NADAC for PIMECROLIMUS 1% CREAM has been published 390 times since Apr 17, 2019, and over the history we have for it it has declined 51.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.3861 per GM |
|---|---|
| All-time high | $7.8776 (Mar 11, 2020) |
| All-time low | $2.4325 (Aug 20, 2025) |
| 52-week high | $4.5850 |
| 52-week low | $2.4455 |
| Median price | $3.9773 |
| Average price | $4.4553 |
| Largest weekly change | +42.1% (Apr 21, 2021) |
| Weeks tracked | 390 |
| Tracking since | Apr 17, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pimecrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIMECROLIMUS 1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for PIMECROLIMUS 1% CREAM, manufactured by Actavis Pharma, Inc., is $3.3861 per GM (NDC 00591294487), effective Sep 30, 2026.
How has the price of PIMECROLIMUS 1% CREAM changed over time?
Over the history we have for it, the NADAC for PIMECROLIMUS 1% CREAM has declined 51.2%. It has been tracked across 390 weekly CMS publications since Apr 17, 2019.
What are the highest and lowest recorded NADAC prices for PIMECROLIMUS 1% CREAM?
Since Apr 17, 2019, the NADAC for PIMECROLIMUS 1% CREAM has ranged from a low of $2.4325 (Aug 20, 2025) to a high of $7.8776 (Mar 11, 2020), with a median of $3.9773 per GM.
Are there cheaper alternatives to PIMECROLIMUS 1% CREAM?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PIMECROLIMUS 1% CREAM, is $3.1048 per GM — about 8% below PIMECROLIMUS 1% CREAM.
Who manufactures PIMECROLIMUS 1% CREAM?
PIMECROLIMUS 1% CREAM (NDC 00591294487) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.